These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26432403)

  • 1. Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.
    Anz D; Rapp M; Eiber S; Koelzer VH; Thaler R; Haubner S; Knott M; Nagel S; Golic M; Wiedemann GM; Bauernfeind F; Wurzenberger C; Hornung V; Scholz C; Mayr D; Rothenfusser S; Endres S; Bourquin C
    Cancer Res; 2015 Nov; 75(21):4483-93. PubMed ID: 26432403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
    Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
    J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells.
    Vences-Catalán F; Rajapaksa R; Srivastava MK; Marabelle A; Kuo CC; Levy R; Levy S
    Cancer Res; 2015 Nov; 75(21):4517-26. PubMed ID: 26329536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity.
    Cordiglieri C; Marolda R; Franzi S; Cappelletti C; Giardina C; Motta T; Baggi F; Bernasconi P; Mantegazza R; Cavalcante P
    J Autoimmun; 2014 Aug; 52():74-89. PubMed ID: 24397961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
    Furudate S; Fujimura T; Kambayashi Y; Kakizaki A; Hidaka T; Aiba S
    Anticancer Res; 2017 Jul; 37(7):3461-3471. PubMed ID: 28668835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance.
    Bugno J; Wang L; Yu X; Cao X; Wang J; Huang X; Yang K; Piffko A; Chen K; Luo SY; Naccasha E; Hou Y; Fu S; He C; Fu YX; Liang HL; Weichselbaum RR
    Clin Cancer Res; 2024 Oct; 30(19):4450-4463. PubMed ID: 38691100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated fibroblast-derived interleukin-1β activates protumor C-C motif chemokine ligand 22 signaling in head and neck cancer.
    Huang YH; Chang CY; Kuo YZ; Fang WY; Kao HY; Tsai ST; Wu LW
    Cancer Sci; 2019 Sep; 110(9):2783-2793. PubMed ID: 31325403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular mechanisms of CCL22-mediated attenuation of autoimmune diabetes.
    Bischoff L; Alvarez S; Dai DL; Soukhatcheva G; Orban PC; Verchere CB
    J Immunol; 2015 Apr; 194(7):3054-64. PubMed ID: 25740943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
    Rapp M; Wintergerst MWM; Kunz WG; Vetter VK; Knott MML; Lisowski D; Haubner S; Moder S; Thaler R; Eiber S; Meyer B; Röhrle N; Piseddu I; Grassmann S; Layritz P; Kühnemuth B; Stutte S; Bourquin C; von Andrian UH; Endres S; Anz D
    J Exp Med; 2019 May; 216(5):1170-1181. PubMed ID: 30910796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL1 is a major regulatory T cell attracting factor in human breast cancer.
    Kuehnemuth B; Piseddu I; Wiedemann GM; Lauseker M; Kuhn C; Hofmann S; Schmoeckel E; Endres S; Mayr D; Jeschke U; Anz D
    BMC Cancer; 2018 Dec; 18(1):1278. PubMed ID: 30572845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells.
    Faget J; Biota C; Bachelot T; Gobert M; Treilleux I; Goutagny N; Durand I; Léon-Goddard S; Blay JY; Caux C; Ménétrier-Caux C
    Cancer Res; 2011 Oct; 71(19):6143-52. PubMed ID: 21852386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma.
    Enarsson K; Lundgren A; Kindlund B; Hermansson M; Roncador G; Banham AH; Lundin BS; Quiding-Järbrink M
    Clin Immunol; 2006 Dec; 121(3):358-68. PubMed ID: 16934529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL22 Signaling in the Tumor Environment.
    Röhrle N; Knott MML; Anz D
    Adv Exp Med Biol; 2020; 1231():79-96. PubMed ID: 32060848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection.
    Riezu-Boj JI; Larrea E; Aldabe R; Guembe L; Casares N; Galeano E; Echeverria I; Sarobe P; Herrero I; Sangro B; Prieto J; Lasarte JJ
    J Hepatol; 2011 Mar; 54(3):422-31. PubMed ID: 21129807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL22-producing CD8α- myeloid dendritic cells mediate regulatory T cell recruitment in response to G-CSF treatment.
    Layseca-Espinosa E; Korniotis S; Montandon R; Gras C; Bouillié M; Gonzalez-Amaro R; Dy M; Zavala F
    J Immunol; 2013 Sep; 191(5):2266-72. PubMed ID: 23878314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.
    Le Mercier I; Poujol D; Sanlaville A; Sisirak V; Gobert M; Durand I; Dubois B; Treilleux I; Marvel J; Vlach J; Blay JY; Bendriss-Vermare N; Caux C; Puisieux I; Goutagny N
    Cancer Res; 2013 Aug; 73(15):4629-40. PubMed ID: 23722543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fucoidan inhibits CCL22 production through NF-κB pathway in M2 macrophages: a potential therapeutic strategy for cancer.
    Sun J; Sun J; Song B; Zhang L; Shao Q; Liu Y; Yuan D; Zhang Y; Qu X
    Sci Rep; 2016 Oct; 6():35855. PubMed ID: 27775051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.
    Mailloux AW; Young MR
    J Immunol; 2009 Mar; 182(5):2753-65. PubMed ID: 19234170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumors establish resistance to immunotherapy by regulating T
    Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.
    Redjimi N; Raffin C; Raimbaud I; Pignon P; Matsuzaki J; Odunsi K; Valmori D; Ayyoub M
    Cancer Res; 2012 Sep; 72(17):4351-60. PubMed ID: 22798340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.